BioPharma Dive August 15, 2024
The approval of Niktimvo in graft-versus-host disease hands Incyte another immune system-regulating medication that analysts see as valuable, especially if its label expands.
The Food and Drug Administration has approved another medicine for a rare condition that arises after a bone marrow or stem cell transplant, when donor cells treat the new body they’ve been placed into as a world of foreign pathogens and start attacking its healthy tissues.
The condition, known as graft-versus-host disease or GVHD, is a leading cause of death from bone marrow transplants, which are used to treat certain blood cancers, solid tumors and immune disorders. By some estimates, close to one-third of those who undergo this procedure experience GVHD.
In 2017, the FDA cleared Imbruvica,...
Today's Sponsors
Today's Sponsor